查看購物車
  • Simplified Chinese
  • English
  • Japanese
2031年北美青光眼治療市場預測 - 區域分析 - 按藥物類別、適應症和配銷通路
市場調查報告書
商品編碼
1764891

2031年北美青光眼治療市場預測 - 區域分析 - 按藥物類別、適應症和配銷通路

North America Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 132 Pages | 訂單完成後即時交付

價格

2023 年北美青光眼治療市場價值為 26.3452 億美元，預計到 2031 年將達到 34.2164 億美元；預計 2023 年至 2031 年的複合年成長率為 3.3%。

青光眼發生率不斷上升推動北美青光眼治療市場

青光眼是一種因視神經受損引起的眼部疾病，最終可能導致完全失明。青光眼患者可能會逐漸經歷神經組織損失，如果不及時治療，會導致視力下降或失明。全球青光眼病例正在顯著增加。根據青光眼研究基金會的數據，到 2040 年，全球預計將有 2,200 萬人因青光眼而失明。此外，根據世界衛生組織的數據，青光眼是全球主要的失明原因，影響超過 6,000 萬人，導致約 450 萬人失明。根據 2021 年 1 月發表在《視覺與眼科學研究協會》（ARVO）雜誌上的一篇文章的估計，到 2030 年底、2040 年底和 2050 年底，墨西哥患有青光眼的人數將分別達到 250 萬人、300 萬人和 340 萬人。隨著全球青光眼病例數量的不斷增加，對青光眼治療的需求也日益成長。用於治療青光眼的醫療和外科手術主要著重於降低眼壓 (IOP)。前列腺素類似物是廣泛推薦的藥物之一，可透過促進眼球引流來有效降低眼壓。由於其療效顯著且不良反應有限，這些產品已成為青光眼治療的主流方案。

北美洲青光眼治療市場概況

根據美國人口參考局 2019 年的數據，到 2060 年，美國 65 歲及以上人口的數量預計將從 2018 年的 5,200 萬（佔總人口的 16%）加倍，增至近 9,500 萬人（佔總人口的 23%）。美國眼科學會 2019 年進行的一項研究表明，到 2050 年，美國 70-75 歲人群估計將有近 732 萬人患有原發性開角型青光眼 (POAG)。因此，美國青光眼治療市場的成長主要受眼部疾病盛行率上升的推動，尤其是在老年人口中。美國佔北美青光眼治療市場的最大佔有率。

市場參與者採用的各種有機和無機成長策略也為美國青光眼治療市場的發展做出了顯著貢獻。以下列舉了一些此類成長策略。

2023年10月，Stuart Therapeutics與Glaukos簽署了Stuart Therapeutics ST-113候選藥物的授權協議，該藥物旨在保護青光眼患者的神經。 2022年8月，愛爾康收購了Aerie Pharmaceuticals, Inc.。這項交易證實了愛爾康對眼科藥物領域的承諾，並有望透過增加更廣泛的藥物研發能力來增強其現有的商業專長，從而最大限度地提升其多元化產品組合的價值。北美青光眼治療市場收入及預測（2031年）（百萬美元）

北美青光眼治療市場細分

北美青光眼治療市場按藥物類別、適應症、配銷通路和國家分類。

依藥物類別，北美青光眼治療市場細分為BETA受體阻斷劑、α腎上腺素激動劑、前列腺素類似物、碳酸酐酶抑制劑、複方藥物及其他。前列腺素類似物在2023年佔據了最大的市場。

根據適應症，北美青光眼治療市場分為開角型青光眼、閉角型青光眼和其他類型。 2023年，開角型青光眼佔了最大的市場。

按配銷通路分類，北美青光眼治療市場分為醫院藥房、零售藥房和線上藥房。 2023年，醫院藥局佔了最大的市場佔有率。

按國家/地區分類，北美青光眼治療市場分為美國、加拿大和墨西哥。 2023年，美國佔據了北美青光眼治療市場的主導地位。

Alcon AG、AbbVie Inc、Bausch & Lomb Inc、Fera Pharmaceuticals, LLC、Viatris Inc、Novartis AG、Sun Pharmaceutical Industries Ltd、Teva Pharmaceuticals Industries Ltd、Thea Pharma Inc 和 Santen Pharmaceutical Co., Ltd. 是北美青光眼治療市場領先的公司。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力

第3章：研究方法

  • 二次研究
  • 初步研究
    • 假設表述：
    • 宏觀經濟因素分析：
    • 顯影基數：
    • 數據三角測量：
    • 國家級資料：

第4章：北美青光眼治療市場格局

  • 概述
  • PEST分析

第5章：北美青光眼治療市場-關鍵市場動態

  • 市場促進因素
    • 青光眼發生率不斷上升
    • 產品發布、合作和收購的數量不斷增加
  • 市場限制
    • 藥物治療方案依從性問題
  • 市場機會
    • 穿戴式科技的發展
  • 未來趨勢
    • 新型藥物輸送方法的開發
  • 促進因素和限制因素的影響：

第6章：青光眼治療市場－北美分析

  • 2021-2031年青光眼治療市場收入
  • 青光眼治療市場預測分析

第7章：北美青光眼治療市場分析－依藥物類別

  • BETA受體阻斷劑
  • α腎上腺素激動劑
  • 前列腺素類似物
  • 碳酸酐酶抑制劑
  • 聯合用藥
  • 其他

第 8 章：北美青光眼治療市場分析 - 按適應症

  • 開角型青光眼
  • 閉角型青光眼
  • 其他

第9章：北美青光眼治療市場分析－按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 10 章：北美青光眼治療市場 - 國家分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

第 11 章：青光眼治療市場-產業格局

  • 青光眼治療市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第12章：公司簡介

  • Alcon AG
  • AbbVie Inc
  • Bausch & Lomb Inc
  • Fera Pharmaceuticals, LLC
  • Viatris Inc
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Thea Pharma Inc
  • Santen Pharmaceutical Co., Ltd.

第 13 章：附錄

Product Code: BMIRE00031610

The North America glaucoma therapeutics market was valued at US$ 2,634.52 million in 2023 and is expected to reach US$ 3,421.64 million by 2031; it is estimated to register a CAGR of 3.3% from 2023 to 2031.

Mounting Incidence of Glaucoma Disease Fuels North America Glaucoma Therapeutics Market

Glaucoma is an eye disorder caused due to the damaged optic nerve, which can eventually lead to total blindness. Glaucoma patients may experience a gradual loss of nerve tissue, resulting in vision impairment or blindness if left untreated. Glaucoma cases are increasing significantly across the world. As per the Glaucoma Research Foundation, an estimated 22 million people worldwide would attain blindness due to glaucoma by 2040. Further, Glaucoma is a leading cause of blindness worldwide, affecting over 60 million people and leading to approximately 4.5 million cases of blindness, according to the World Health Organization. According to estimates provided in an article published in the Association for Research in Vision and Ophthalmology (ARVO) Journal in January 2021, the number of people suffering from glaucoma in Mexico would reach 2.5 million, 3 million, and 3.4 million by the end of 2030, 2040, and 2050, respectively. The demand for glaucoma treatments is increasing with the rising number of glaucoma cases in the global population. Medical and surgical procedures meant to manage this disease focus on lowering intraocular pressure (IOP). Prostaglandin analogs are among the drugs widely recommended for effectively reducing IOP by promoting better drainage from the eye. These products have been mainstream glaucoma treatment due to their efficacy and limited adverse effects.

North America Glaucoma Therapeutics Market Overview

As per the Population Reference Bureau 2019, the number of individuals aged 65 and above in the US is estimated to double from 52 million (16% of the total population) in 2018 to nearly 95 million (23% of the total population) by 2060. A study conducted by the American Academy of Ophthalmology in 2019 states that nearly 7.32 million people aged 70-75 is estimated to be affected by primary open-angle glaucoma (POAG) in the US by 2050. Thus, the glaucoma therapeutics market growth in the US is primarily driven by the increasing prevalence of eye diseases, especially in the geriatric population. The US accounts for the largest share of the glaucoma therapeutics market in North America.

Various organic and inorganic growth strategies adopted by market players also contribute notably to the glaucoma therapeutics market progress in the US. A few of such growth strategies are mentioned below.

In October 2023, Stuart Therapeutics and Glaukos signed a license agreement for Stuart Therapeutics' ST-113 drug candidate designed for neuroprotection in glaucoma. In August 2022, Alcon acquired Aerie Pharmaceuticals, Inc. This transaction confirms Alcon's commitment to the ophthalmic pharmaceutical space, and it is expected to enhance its existing commercial expertise by adding broader pharmaceutical R&D capabilities, thereby maximizing the value of its diversified portfolio. North America Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)

North America Glaucoma Therapeutics Market Segmentation

The North America glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the North America glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the North America glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the North America glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the North America glaucoma therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the North America glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, Fera Pharmaceuticals, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the North America glaucoma therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. North America Glaucoma Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. North America Glaucoma Therapeutics Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Mounting Incidence of Glaucoma Disease
    • 5.1.2 Increasing Number of Product Launches, Collaborations, and Acquisitions
  • 5.2 Market Restraints
    • 5.2.1 Medication Regimen Compliance Issues
  • 5.3 Market Opportunities
    • 5.3.1 Development of Wearable Technologies
  • 5.4 Future Trends
    • 5.4.1 Development of Novel Drug Delivery Methods
  • 5.5 Impact of Drivers and Restraints:

6. Glaucoma Therapeutics Market - North America Analysis

  • 6.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • 6.2 Glaucoma Therapeutics Market Forecast Analysis

7. North America Glaucoma Therapeutics Market Analysis - by Drug Class

  • 7.1 Beta Blockers
    • 7.1.1 Overview
    • 7.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Alpha Adrenergic Agonists
    • 7.2.1 Overview
    • 7.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Prostaglandins Analogues
    • 7.3.1 Overview
    • 7.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Carbonic Anhydrase Inhibitors
    • 7.4.1 Overview
    • 7.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Combination Drugs
    • 7.5.1 Overview
    • 7.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Glaucoma Therapeutics Market Analysis - by Indication

  • 8.1 Open Angle Glaucoma
    • 8.1.1 Overview
    • 8.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Angle Closure Glaucoma
    • 8.2.1 Overview
    • 8.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Glaucoma Therapeutics Market Analysis - by Distribution Channel

  • 9.1 Hospital Pharmacy
    • 9.1.1 Overview
    • 9.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Retail Pharmacy
    • 9.2.1 Overview
    • 9.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Online Pharmacy
    • 9.3.1 Overview
    • 9.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Glaucoma Therapeutics Market - Country Analysis

  • 10.1 North America
    • 10.1.1 North America: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)
      • 10.1.1.1 North America: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.2.1 United States: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.2.2 United States: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.1.1.2.3 United States: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.3 Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.3.1 Canada: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.3.2 Canada: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.1.1.3.3 Canada: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.4 Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.4.1 Mexico: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.4.2 Mexico: Glaucoma Therapeutics Market Breakdown, by Indication
        • 10.1.1.4.3 Mexico: Glaucoma Therapeutics Market Breakdown, by Distribution Channel

11. Glaucoma Therapeutics Market - Industry Landscape

  • 11.1 Growth Strategies in Glaucoma Therapeutics Market
  • 11.2 Organic Growth Strategies
    • 11.2.1 Overview
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview

12. Company Profiles

  • 12.1 Alcon AG
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 AbbVie Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Bausch & Lomb Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Fera Pharmaceuticals, LLC
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Viatris Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Novartis AG
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Sun Pharmaceutical Industries Ltd
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Teva Pharmaceutical Industries Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Thea Pharma Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Santen Pharmaceutical Co., Ltd.
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. North America Glaucoma Therapeutics Market Segmentation
  • Table 2. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 3. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 4. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 5. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 6. North America: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Country
  • Table 7. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 8. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 9. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 10. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 11. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 12. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 13. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 14. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 15. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 16. Recent Organic Growth Strategies in Glaucoma Therapeutics Market
  • Table 17. Recent Inorganic Growth Strategies in the Glaucoma Therapeutics Market
  • Table 18. Glossary of Terms

List Of Figures

  • Figure 1. North America Glaucoma Therapeutics Market Segmentation, by Country
  • Figure 2. PEST Analysis
  • Figure 3. Glaucoma Therapeutics Market - Key Market Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • Figure 6. Glaucoma Therapeutics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 7. Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Glaucoma Therapeutics Market Share (%) - by Indication (2023 and 2031)
  • Figure 14. Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Glaucoma Therapeutics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 18. Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. North America Glaucoma Therapeutics Market, by Key Country - Revenue (2023) (US$ Million)
  • Figure 22. North America: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 23. United States: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Canada: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Mexico: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Growth Strategies in Glaucoma Therapeutics Market